Ashlan J Kunz Coyne, Sara Alosaimy, Kristen Lucas, Abdalhamid M Lagnf, Taylor Morrisette, Kyle C Molina, Alaina DeKerlegand, Melanie Rae Schrack, S Lena Kang-Birken, Athena L V Hobbs, Jazmin Agee, Nicholson B Perkins, Mark Biagi, Michael Pierce, James Truong, Justin Andrade, Jeannette Bouchard, Tristan Gore, Madeline A King, Benjamin M Pullinger, Kimberly C Claeys, Shelbye Herbin, Reese Cosimi, Serina Tart, Michael P Veve, Bruce M Jones, Leonor M Rojas, Amy K Feehan, Marco R Scipione, Jing J Zhao, Paige Witucki, Michael J Rybak
The rise of multidrug-resistant (MDR) pathogens, especially MDR Gram-negatives, poses a significant challenge to clinicians and public health. These resilient bacteria have rendered many traditional antibiotics ineffective, underscoring the urgency for innovative therapeutic solutions. Eravacycline, a broad-spectrum fluorocycline tetracycline antibiotic approved by the FDA in 2018, emerges as a promising candidate, exhibiting potential against a diverse array of MDR bacteria, including Gram-negative, Gram-positive, anaerobic strains, and Mycobacterium...
November 29, 2023: Microbiology Spectrum